To sign up for our free research reports and newsletters, visit http://beaconequityresearch.com/. For more information on our research programs, please contact: Jeff Bishop at editor@beaconequityresearch.com
Baywood International, Inc. (OTCBB: BYWD) Up 33.33% on Monday
Detailed quote: http://beaconequityresearch.com/BYWD
December 17, 2007 - New Research on Resveratrol Reveals Benefit in Curbing Insulin Resistance
Baywood International, Inc. (OTCBB:BYWD) ("Company") announced that resveratrol, an antioxidant found in red wine, may counter type 2 diabetes and insulin resistance, according to a new study.
Insulin is a hormone that controls blood sugar. Insulin resistance occurs when the body becomes less sensitive to insulin. This condition can lead to type 2 diabetes. Chinese scientists report that resveratrol curbs insulin resistance in mice. These scientists, including Cheng Sun and Qiwei Zhai of the
"According to (our) findings, people might need to drink about three liters of red wine each day to get sufficient resveratrol - about 15 milligrams - for its biological effects," Zhai said in a news release, although the researchers did not recommend that anyone rely on wine to help their insulin sensitivity.
Resveratrol is found in grapes (especially in red wine), raspberries, peanuts, and other plants that use resveratrol to defend against threats such as disease. Sun's team found that insulin-resistant mice become more sensitive to insulin when given resveratrol. The scientists' experiments with cells in test tubes show that resveratrol spurs a gene called SIRT1 to become more active, boosting insulin sensitivity.
According to the American Diabetes Association, (http://www.diabetes.org/), there are 20.8 million children and adults in the
The total annual economic cost of diabetes in 2002 (latest year for which data is available) was estimated to be $132 billion. Direct medical expenditures totaled $92 billion and comprised $23.2 billion for diabetes care, $24.6 billion for chronic diabetes-related complications, and $44.1 billion for excess prevalence of general medical conditions. Indirect costs resulting from lost workdays, restricted activity days, mortality, and permanent disability due to diabetes totaled $40.8 billion. Furthermore, one out of every 10 health care dollars spent in the
During the third quarter of this year, the Company's wholly-owned subsidiary, Nutritional Specialties, Inc./dba LifeTime(R), launched Resveratrol Life Tonic(TM) in liquid form for enhanced bioavailability. The product's powerful antioxidant properties include 300 mg of resveratrol extract in each one ounce serving, which is equivalent to 1,300 glasses of red wine. For more information, visit www.lifetimevitamins.com/products/lifetime_resveratrol.html.
Transax International Limited (OTCBB: TNSX) Up 47.06% on Monday
Detailed quote: http://beaconequityresearch.com/TNSX
December 17, 2007 - Transax International Signs Binding Letter of Intent to Sell
Transax International Limited (Transax) (OTCBB: TNSX), a network solutions company for healthcare providers and health insurance companies, announced today it has signed a binding Letter of Intent to sell its Brazil operations ("Medlink") to a private group of technology investors in Brazil for U.S. $5.6 million cash and assumption of $2.65 million in debt. An additional payment of up to U.S. $1.25 million is possible subject to the company reaching certain performance levels during 2008, bringing the total potential value of the transaction to U.S. $9.5 million.
Under terms of the agreement, the acquiring investors will pay cash and retain operating control of Medlink's assets and intellectual property. The investors will pay Transax U.S. $200,000 upon signing of the binding Letter of Intent, U.S. $600,000 on closing of the transaction and U.S. $4,800,000 by 24 equal monthly payments of U.S. $200,000. The investors will also assume $2.65 million in debt. The transaction is expected to close within 30 days and is subject to approval of Transax shareholders.
Stephen Walters, President & CEO of Transax, commented, "We are very pleased to have been able to reach an agreement to monetize our Brazilian operations. Transax will continue to retain exclusive licensing rights outside of Latin America including the
Continental Fuels, Inc. (OTCBB: CFUL) Up 44.12% on Monday
Detailed quote: http://beaconequityresearch.com/CFUL
December 14, 2007 - Continental Fuels Completes Acquisition of Geer Tank Trucks -
With conventional financing provided by Sheridan Asset Management, LLC of New York, Continental Fuels, Inc. (OTC BB: CFUL) (FWB: CIQB) has completed the purchase of all of the outstanding stock of Geer Tank Trucks, Inc. (http://www.geertanktrucks.com/), a crude oil purchasing company founded in 1945 with five locations in North Texas and nearly $50 million in annual revenue. In this single transaction in which Geer becomes a wholly owned subsidiary of Continental, Continental has completed the next phase of its business plan by securing a consistent supply of crude oil, all of the equipment necessary to transport and process that crude and access to major crude oil pipelines to efficiently deliver the crude to market.
The transaction is the second major acquisition completed by Continental during the year. In April, Continental acquired the Brownsville Port Facility (http://www.portofbrownsville.com/) and light crude trading business of Universal Property Development and Acquisition Corporation (OTC BB: UPDA) (FWB: UP1) (http://www.universalpropertydevelopment.com/) in a transaction that resulted in UPDA acquiring a controlling interest in Continental. Since that time, Continental has expanded the storage capacity of its port facility and established significant contracts for the sale and delivery of light crude condensate originating from that facility.
In addition to financing this purchase,
The Geer acquisition includes 4 pipeline terminals with connections to major pipeline companies such as Colonial, Teppco and Plains and 5 service yards in various locations throughout North Texas, more than twenty 200 bbl transports, 50 frac tanks, water hauling and disposal facilities incorporating 2 commercial salt water disposal wells and other assets and equipment invaluable to Continental's continuing development of its business model.
"Completing this acquisition represents another leap forward in the development of our business," remarked Continental CEO Tim Brink. "While the revenue it brings is very important, the incredible opportunities it presents cannot be overstated. The assets and business of this company correspond perfectly with the plans we have developed. In the time we have been working with the Geer management, much of which will remain intact, we have identified several additional sources of revenue and opportunities for growth and negotiated significant increases in sales margins. Continental will now have port facilities and contracts for the purchase, storage, sale and delivery of light crude in South Texas and sources, facilities and equipment to transport and deliver and contracts to purchase and sell crude in
DealerAdvance(TM), Inc. (OTCBB: DLAV) Up 38.78% on Monday
Detailed quote: http://beaconequityresearch.com/DLAV
December 17, 2007 - New Dealer Contracts Bolster Revenue for DealerAdvance
DealerAdvance(TM), Inc. (OTCBB:DLAV), announced today that the company has converted three DealerAdvance(TM) clients to its new and growing WebDA(TM) product.
Steven Humphries, DealerAdvance CEO said, "Our primary goal over the past several months has been to open new dealers and convert our older dealers whose contracts had or were expiring to our new WebDA product. We are pleased to announce that long-time customers Gresham Ford (
Gresham Ford General Manager Bess Wills commented, "We've been with DealerAdvance from the beginning and are very excited about moving over to the new WebDA product. Our sales people and sales management like the product due to it being so user-friendly."
VP of Sales Dave Scaturro said, "It's all about customer retention and customer satisfaction. Our goal is to have happy customers that will do business with the company for years and years. Gresham Ford, Pierre Dodge and Palmetto Nissan have been long customers of the company and we are pleased to have them continue with our new product."
WebDA(TM) is the newest iteration of DLAV's "CRM" application. The system is also offers the Nokia 800 hand-held devise that is web based and is available at a fraction of the cost of the original DLAV system. The original server based system is now being replaced in the almost 100 dealerships previously being served. According to Humphries dealers that have utilized the original DealerAdvance(TM) system have shown a 90% increased in captured customer data and a 30% increase in appointment setting. "It's all about sales," says Humphries, "theirs and ours."
Micro Imaging Technology, Inc. (OTCBB: MMTC) Up 20.00% on Monday
Detailed quote: http://beaconequityresearch.com/MMTC
December 17, 2007 - MIT Successfully Completes Rigorous Performance Tests
Micro Imaging Technology, Inc. (OTCBB: MMTC) announces the successful completion of rigorous microorganism identification accuracy testing. The Company tested three MIT Rapid Microbial ID Systems for identification accuracy on a total of eight different species' strains of E.coli, Staphylococcus aureus and Salmonella. The MIT 1000 System produces results in less than ten minutes after completion of the culturing process without using chemicals, reagents or DNA processing.
The objectives of the test were twofold. The first objective was to determine the System's ability to accurately identify specific bacterial species strains that were programmed into the System's database. The second objective was to determine the System's robustness to accurately identify the correct species when presented with a strain of that species not programmed into the System's database. The organisms were chosen based on customer interest and frequency of reported contamination cases found in food processing, food products, hospitals, and other public environments.
Of the 151 tests performed, 40% were tested with the actual species strain. The remaining tests provided accuracy performance of specific species strains not in the System's database. The results showed that the three systems achieved 100% identification accuracy for all species when the specific strain was programmed into the Product's database and 91% accuracy for all testing conducted.
MIT's CTO Dr. David Haavig stated, "The perfect results achieved for those species strains within our database met our expectations and we are pleased to see the robust performance of the MIT 1000 System when presented with a species strain not contained in the database. This will enable our customers to confidently use our System with a wide variety of organisms and obtain consistent and reliable identification results. This performance also suggests that minor adjustments to our algorithms may improve the performance to obtain near 100% accuracy for all strains of a species."
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN THIS DOCUMENT. ALL INFORMATION PROVIDED HERE IS MERELY INFORMATIONAL AND IS NOT INTENDED TO BE A RECOMMENDATION TO BUY OR SELL ANY SECURITY. YOU SHOULD CONSULT A LICENSED INVESTMENT PROFESSIONAL BEFORE MAKING ANY INVESTMENT DECISION. All material herein has been prepared by us based upon information believed to be reliable. The information contained herein is not guaranteed by us to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not always approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. We are not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed or mentioned herein. Beacon Equity Research has not been compensated by any of the companies covered in this release. It is the policy of Beacon Research and its affiliates to sell any stock received for services, which may cause the stock price to become depressed. Our affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. We may sell shares for less than the target price given in this opinion, or at any time following the issuance of this announcement. We will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Beacon Research and its owners undertake no obligation to update such statements.
